What Makes AcelRx Pharmaceuticals (ACRX) a New Buy Stock
- AcelRx Pharmaceuticals (ACRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 08/22/2023
|
AcelRx Pharmaceuticals, Inc. (ACRX) Q2 2023 Earnings Call Transcript
- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Raffi Asadorian – Chief Financial Officer Vince Angotti – Chief Executive Officer Pam Palmer – Founder and Chief Medical Officer Conference Call Participants Thomas Yip – H.C. Wainwright Laura Suriel – Alliance Global Operator Welcome to the AcelRx Second Quarter 2023 Financial Results Conference Call.
- 08/10/2023
|
AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Tops Revenue Estimates
- AcelRx Pharmaceuticals (ACRX) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to loss of $1.20 per share a year ago.
- 08/10/2023
|
AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update
- Capital raise closed in July, led by new healthcare investors; provides access to up to $26.3 million in capital, with $10 million immediately available AcelRx awaits response to Emergency Use Authorization (EUA) of Niyad™ submitted to the FDA in April; registrational study set to initiate in Q4 2023 Proforma $17.4 million in cash as of June 30, 2023, including gross proceeds from financing closed in July 2023 Senior debt with Oxford fully repaid in Q2 2023 Webcast and conference call to be held today at 4:30 p.m. EDT SAN MATEO, Calif.
- 08/10/2023
|
AcelRx to Host Second Quarter 2023 Financial Results Call and Webcast on August 10, 2023
- HAYWARD, Calif. , July 27, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release second quarter 2023 financial results after market close on Thursday, August 10, 2023, then host a live webcast and conference call at 4:30 p.m.
- 07/27/2023
|
AcelRx Pharmaceuticals Announces Closing of Previously Announced Private Placement Priced At-The-Market Under Nasdaq Rules
- Transformative capital raise, led by new investors including Nantahala Capital Management The private placement provides access to up to $26.3 million of gross proceeds upon the exercise of the milestone-affected warrants HAYWARD, Calif. , July 21, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the closing of its previously announced private placement of common stock, pre-funded warrants and common warrants for aggregate gross proceeds to the Company of $10 million, before deducting the placement agent's fees and other offering expenses payable by the Company, with an additional potential $16.3 million upon the exercise of the common warrants, which include an acceleration feature should the Company achieve certain performance milestones.
- 07/21/2023
|
AcelRx Pharmaceuticals Announces $10 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
- Upon the achievement of certain milestones accelerating the warrants' expiration date, AcelRx may receive an additional $16.3 million of gross proceeds if the common warrants are exercised in full HAYWARD, Calif. , July 18, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 5,340,591 shares of common stock, at a purchase price of $1.36 per share of common stock, and pre-funded warrants to purchase 2,012,356 shares of common stock at a purchase price of $1.359 per pre-funded warrant (the "Pre-Funded Warrants").
- 07/18/2023
|
AcelRx Pharmaceuticals (ACRX) Reports Break-Even Earnings for Q1
- AcelRx Pharmaceuticals (ACRX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.80. This compares to loss of $1.20 per share a year ago.
- 05/10/2023
|
AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
- Request for Emergency Use Authorization of Niyad™ submitted to the FDA in April Divestment of DSUVIA® to Alora Pharmaceuticals closed April 3, 2023 $13.4 million in cash as of March 31, 2023 Webcast and conference call to be held today at 4:30 p.m. EDT HAYWARD, Calif.
- 05/10/2023
|
AcelRx Pharmaceuticals Announces Closing of Divestment of DSUVIA® to Alora Pharmaceuticals
- In connection with closing, AcelRx received approximately $2.7 million from Alora Pharmaceuticals and Aguettant AcelRx announces full repayment of its senior loan with Oxford Finance HAYWARD, Calif. , April 5, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the closing of its divestment of DSUVIA® to Alora Pharmaceuticals (Alora).
- 04/05/2023
|
AcelRx Pharmaceuticals Inc. (ACRX) Q4 2022 Earnings Call Transcript
- AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX ) Q4 2022 Results Conference Call March 30, 2023 4:30 PM ET Company Participants Raffi Asadorian - Chief Financial Officer Vincent Angotti - Chief Executive Officer Pamela Palmer - Chief Medical Officer and Co-Founder Conference Call Participants Brandon Folkes - Cantor Fitzgerald Operator Welcome to the AcelRx 2022 Full Year and Fourth Quarter Financial Results Conference Call. This call is being webcast live via the Events page on the Investors section of AcelRx's website at www.acelrx.com.
- 03/30/2023
|
AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Lags Revenue Estimates
- AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of -900% and 97.04%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 03/30/2023
|
AcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate Update
- Divestment of DSUVIA® to Alora Pharmaceuticals expected to close the week of April 3, 2023 AcelRx advancing its proprietary Niyad™ nafamastat program with FDA Breakthrough designation in line with a strategic focus on late-stage assets Near-term corporate milestones expected by the end of Q2 2023 include Niyad Emergency Use Authorization submission and the filing of a New Drug Application for Fedsyra™, the first of two pre-filled syringe product candidates $20.8 million in cash and short-term investments as of December 31, 2022 Webcast and conference call to be held today at 4:30 p.m. EDT HAYWARD, Calif.
- 03/30/2023
|
AcelRx to Host Full Year and Fourth Quarter 2022 Financial Results Call and Webcast on March 30, 2023
- HAYWARD, Calif. , March 21, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release full year and fourth quarter financial results for 2022 after the market close on Thursday, March 30, 2023.
- 03/21/2023
|
AcelRx Pharmaceuticals, Inc. (ACRX) Q3 2022 Results - Earnings Call Transcript
- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX ) Q3 2022 Results Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Raffi Asadorian - Chief Financial Officer Vincent Angotti - Chief Executive Officer Pamela Palmer - Chief Medical Officer and Co-Founder Conference Call Participants Brandon Folkes - Cantor Fitzgerald Thomas Lee - HC Wainwright & Company Operator Welcome to the AcelRx Third Quarter 2022 Earnings Call. This call is being webcast live via the Events page of the Investors section of AcelRx's website at www.acelrx.com.
- 11/14/2022
|
AcelRx Pharmaceuticals (ACRX) Reports Q3 Loss, Misses Revenue Estimates
- AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 21.67% and 7.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/14/2022
|
AcelRx: The Catalogue Of Catalysts - Including A Big One That Will Do Investors Well
- AcelRx's 2Q22 Earnings Release and Call provided little tangible news. However, it becomes more and more obvious that ACRX's management is fully shifting the focus from commercial DSUVIA to launching the Syringes products and Niyad.
- 08/18/2022
|
AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vincent Angotti on Q2 2022 Results - Earnings Call Transcript
- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Raffi Asadorian - CFO Vincent Angotti - CEO Pamela Palmer - Chief Medical Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Ed Arce - HC Wainwright & Company Operator Welcome to the AcelRx Second Quarter, 2022 Earnings Call. This call is being webcast live on the Events page of the Investors section of AcelRx's website at www.acelrx.com.
- 08/11/2022
|
AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Misses Revenue Estimates
- AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 0% and 5%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/11/2022
|
Why Is AcelRx (ACRX) Stock up 26% Today?
- Source: Shutterstock AcelRx Pharmaceuticals (NASDAQ: ACRX ) stock is seeing major gains on Thursday after announcing a presentation for the upcoming Plastic Surgery: The Meeting 2022. That meeting is set to take place from Oct. 27 to Oct. 30 in Boston, Mass.
- 08/11/2022
|
AcelRx Pharmaceuticals (ACRX) Stock: Why It Skyrocketed Over 70% Today
- The stock price of AcelRx Pharmaceuticals (ACRX) skyrocketed over 70% pre-market today. This is why.
- 08/11/2022
|
AcelRx to Host Second Quarter 2022 Financial Results Call and Webcast on August 11, 2022
- HAYWARD, Calif. , July 28, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release second quarter financial results after market close on Thursday, August 11, 2022.
- 07/28/2022
|
What to Know About Buying Penny Stocks on July 8th
- Here's what you need to know about trading penny stocks on July 8th The post What to Know About Buying Penny Stocks on July 8th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 07/08/2022
|
What to Know About Buying Penny Stocks on July 7th
- Here's what you need to know about trading penny stocks on July 6th The post What to Know About Buying Penny Stocks on July 7th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 07/07/2022
|
Hot Penny Stocks That Are Climbing Right Now
- Can these penny stocks climb this week? The post Hot Penny Stocks That Are Climbing Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 06/29/2022
|
Top Penny Stocks Today? 3 You Might Want To Watch Before Next Week
- Penny stocks to watch before the end of the week. The post Top Penny Stocks Today?
- 06/29/2022
|
What to Know About Buying Penny Stocks on June 3rd
- Here's what you need to know about trading penny stocks on June 3rd The post What to Know About Buying Penny Stocks on June 3rd appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 06/03/2022
|
What to Know About Buying Penny Stocks on May 26th
- Here's what you need to know about trading penny stocks today The post What to Know About Buying Penny Stocks on May 26th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 05/26/2022
|
AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Global Investment Conference
- HAYWARD, Calif., May 20, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that Chief Executive Officer, Vince Angotti will present in-person and be available for one-on-one meetings throughout the H.C.
- 05/20/2022
|
Why AcelRx Pharma Shares Are Trading Higher Today?
- The FDA has recently modified the AcelRx Pharmaceuticals Inc's (NASDAQ: ACRX) Dsuvia Risk Evaluation and Mitigation Strategies (REMS) requirements for healthcare setting audits. The Dsuvia REMS program aims to mitigate the risk of respiratory depression resulting from.
- 05/19/2022
|
AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vincent Angotti on Q1 2022 Results - Earnings Call Transcript
- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX ) Q1 2022 Earnings Conference Call May 16, 2022 8:30 AM ET Company Participants Raffi Asadorian - Chief Financial Officer Vincent Angotti - Chief Executive Officer Pamela Palmer - Chief Medical Officer and Co-Founder Conference Call Participants Brandon Folkes - Cantor Fitzgerald Thomas Yip - H.C. Wainwright Robert LeBoyer - Noble Capital Operator Welcome to the AcelRx First Quarter, 2022 Earnings Call.
- 05/16/2022
|
AcelRx Pharmaceuticals (ACRX) Reports Q1 Loss, Lags Revenue Estimates
- AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 0% and 11.60%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/16/2022
|
AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vincent Angotti on Q4 2021 Results - Earnings Call Transcript
- AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vincent Angotti on Q4 2021 Results - Earnings Call Transcript
- 03/10/2022
|
AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Misses Revenue Estimates
- AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 0% and 99.94%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 03/10/2022
|
AcelRx Pharmaceuticals: The Fog Is Getting Thicker
- DSUVIA sales continue to lag expectations. Visibility of earnings and net cash further reduced by Lowell acquisition which is hard to assess at this stage.
- 01/14/2022
|
AcelRx: Battered And Bruised But Ready For Recovery In 2022
- AcelRx continues to be an abysmal investment as the company's flagship product DSUVIA has struggled to gain traction in the middle of COVID-19 headwinds. The lack of DoD orders are hurting the company's quarterly earnings. Consequently, the share price has been crushed and the company's market.
- 01/04/2022
|
Best Penny Stocks to Buy In January 2022? 3 Investors Are Watching
- Are these penny stocks on your January 2022 watchlist? The post Best Penny Stocks to Buy In January 2022?
- 12/31/2021
|
Top Penny Stocks To Buy According To Analysts & Targets Up To 615%
- Penny stocks with hight hopes from analysts. The post Top Penny Stocks To Buy According To Analysts & Targets Up To 615% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 12/31/2021
|
AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vincent Angotti on Q3 2021 Results - Earnings Call Transcript
- AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vincent Angotti on Q3 2021 Results - Earnings Call Transcript
- 11/15/2021
|
AcelRx To Acquire Lowell For $32M, Announces Capital Raise Of $14M
- AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) has agreed to acquire privately-held Lowell Therapeutics Inc for approximately $32.5 million. The deal consideration includes approximately $26 million of contingent consideration payable in cash or stock.
- 11/15/2021
|
AcelRx to Host Third Quarter 2021 Financial Results Call and Webcast on November 15, 2021
- HAYWARD, Calif., Nov. 10, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release third quarter financial results before the market opens on Monday, November 15, 2021.
- 11/10/2021
|
AcelRx Pharmaceuticals: Is Wayne Gretzky Right Or The Puck?
- DSUVIA 2q21 revenues were below my and market expectations. But management provided further details regarding the Europe out-licensing agreement for DSUVIA and the in-licensing agreements. And Formulary Approvals have picked up substantially also indicating gradually increasing interest in the product. Management mentioned discussions about a DSUVIA out-licensing to the Asia-Pacific region.
- 10/02/2021
|
AcelRx Pharmaceuticals to Participate in Two September Investor Conferences
- HAYWARD, Calif., Sept. 10, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that management will be providing an overview of the business and company updates at the H.C.
- 09/10/2021
|
Study Results Announced During Award-Winning Presentation on the Effect of Sufentanil Sublingual Tablet on Outpatient Plastic Surgery at the Annual Miami Cosmetic Surgery Event
- HAYWARD, Calif., Aug. 30, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the results of a study evaluating sufentanil sublingual tablet 30 mcg (SST) for outpatient plastic surgery that was presented during the Miami Cosmetic Surgery (MCS) conference on Friday, August 27 th at the Miami Beach Convention Center in Miami Beach, Florida.
- 08/30/2021
|
Presentation on the Effect of the Administration of Sufentanil Sublingual Tablet on Reducing Post-Operative Recovery Time and Opioid Use in Plastic Surgery at the Annual Miami Cosmetic Surgery Event
- HAYWARD, Calif., Aug. 26, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced an upcoming presentation on the effects of administering sufentanil sublingual tablet 30 mcg (SST) at Miami Cosmetic Surgery held at the Miami Beach Convention Center in Miami Beach, Florida from August 25-27, 2021.
- 08/26/2021
|
5 Penny Stocks To Buy According To Top Wall Street Analysts In 2021
- Analysts say these are penny stocks to buy. Do you agree?
- 08/18/2021
|
AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vincent Angotti on Q2 2021 Results - Earnings Call Transcript
- AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vincent Angotti on Q2 2021 Results - Earnings Call Transcript
- 08/16/2021
|
AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Lags Revenue Estimates
- AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 0.00% and -19.46%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/16/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AcelRx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ACRX
- NEW YORK, Aug. 9, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX) and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-04353, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired AcelRx securities between March 17, 2020 and February 12, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 08/09/2021
|
DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - August 9, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AcelRx Pharmaceuticals, Inc. ("AcelRx" or "the Company") (NASDAQ: ACRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between March 17, 2020 and February 12, 2021, inclusive...
- 08/09/2021
|
ACRX Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds AcelRx Pharmaceuticals, Inc. Shareholders of Class Action and Lead Plaintiff Deadline: August 9, 2021
- New York, New York--(Newsfile Corp. - August 9, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or "the Company") (NASDAQ: ACRX) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired AcelRx securities between March 17, 2020 and February 12, 2021, (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site:...
- 08/09/2021
|
ACRX Final Deadline Today: Rosen, Trusted National Trial Counsel, Encourages AcelRx Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important August 9 Deadline in Securities Class Action - ACRX
- New York, New York--(Newsfile Corp. - August 9, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) between March 17, 2020 and February 12, 2021, inclusive (the "Class Period"), of the important August 9, 2021 lead plaintiff deadline.SO WHAT: If you purchased AcelRx securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees...
- 08/09/2021
|
ACRX Final Deadline Monday: Rosen, a Trusted and Leading Law Firm, Encourages AcelRx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 9 Deadline in Securities Class Action - ACRX
- New York, New York--(Newsfile Corp. - August 6, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) between March 17, 2020 and February 12, 2021, inclusive (the "Class Period"), of the important August 9, 2021 lead plaintiff deadline.SO WHAT: If you purchased AcelRx securities during the Class Period you may be entitled to compensation without payment of any out of pocket...
- 08/06/2021
|
DEADLINE MONDAY ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - August 6, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AcelRx Pharmaceuticals, Inc. ("AcelRx" or "the Company") (NASDAQ: ACRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between March 17, 2020 and February 12, 2021, inclusive...
- 08/06/2021
|
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. (ACRX)
- LOS ANGELES--(BUSINESS WIRE)---- $ACRX #investors--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. (ACRX)
- 08/06/2021
|
ACRX Upcoming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds AcelRx Pharmaceuticals, Inc. Shareholders of Class Action and Lead Plaintiff Deadline: August 9, 2021
- New York, New York--(Newsfile Corp. - August 4, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or "the Company") (NASDAQ: ACRX) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired AcelRx securities between March 17, 2020 and February 12, 2021, (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site:...
- 08/04/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AcelRx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ACRX
- NEW YORK, Aug. 3, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX) and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-04353, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired AcelRx securities between March 17, 2020 and February 12, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 08/03/2021
|
ROSEN, A TOP RANKED LAW FIRM, Encourages AcelRx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 9 Deadline in Securities Class Action – ACRX
- NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) between March 17, 2020 and February 12, 2021, inclusive (the “Class Period”), of the important August 9, 2021 lead plaintiff deadline. SO WHAT: If you purchased AcelRx securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHA
- 08/02/2021
|
Will AcelRx Pharmaceuticals (ACRX) Report Negative Q2 Earnings? What You Should Know
- AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 08/02/2021
|
ACRX Upcoming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds AcelRx Pharmaceuticals, Inc. Investors of Class Action and Lead Plaintiff Deadline: August 9, 2021
- NEW YORK--(BUSINESS WIRE)--Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or "the Company") (NASDAQ: ACRX) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired AcelRx securities between March 17, 2020 and February 12, 2021, (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com
- 08/02/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AcelRx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ACRX
- NEW YORK, July 28, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX) and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-04353, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired AcelRx securities between March 17, 2020 and February 12, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 07/28/2021
|
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. (ACRX)
- BENSALEM, Pa., July 28, 2021 /PRNewswire/ -- Law Offices of Howard G.
- 07/28/2021
|
AcelRx Pharmaceuticals: How The Licensing Agreements Could Become A Shot In The Arm
- On July 14, 2021 ACRX announced it had entered into two licensing agreements.
- 07/27/2021
|
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages AcelRx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ACRX
- NEW YORK, July 26, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) between March 17, 2020 and February 12, 2021, inclusive (the "Class Period"), of the important August 9, 2021 lead plaintiff deadline. SO WHAT: If you purchased AcelRx securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 07/26/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AcelRx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ACRX
- New York, New York--(Newsfile Corp. - July 23, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX) and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-04353, is on behalf of a class consisting of all persons and entities other than Defendants that purchased...
- 07/23/2021
|
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. (ACRX)
- LOS ANGELES, July 23, 2021 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming August 9, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX) securities between March 17, 2020 and February 12, 2021 , inclusive (the "Class Period"). If you suffered a loss on your AcelRx investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/acelrx-pharmaceuticals-inc/.
- 07/23/2021
|
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of AcelRx Pharmaceuticals, Inc. (ACRX) Investors
- LOS ANGELES, July 21, 2021 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX) securities between March 17, 2020 and February 12, 2021 , inclusive (the "Class Period").
- 07/21/2021
|
ACRX Investor Notice: Rosen, Trusted Investor Counsel, Encourages AcelRx Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - ACRX
- New York, New York--(Newsfile Corp. - July 20, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) between March 17, 2020 and February 12, 2021, inclusive (the "Class Period"), of the important August 9, 2021 lead plaintiff deadline.SO WHAT: If you purchased AcelRx securities during the Class Period you may be entitled to compensation without payment of any out of...
- 07/20/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AcelRx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ACRX
- NEW YORK, July 18, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX) and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-04353, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired AcelRx securities between March 17, 2020 and February 12, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 07/18/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AcelRx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ACRX
- NEW YORK, July 18, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX) and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-04353, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired AcelRx securities between March 17, 2020 and February 12, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 07/18/2021
|
ACRX ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages AcelRx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important August 9 Deadline in Securities Class Action - ACRX
- New York, New York--(Newsfile Corp. - July 17, 2021) - WHY: New York, N.Y., July 17, 2021. Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) between March 17, 2020 and February 12, 2021, inclusive (the "Class Period"), of the important August 9, 2021 lead plaintiff deadline.SO WHAT: If you purchased AcelRx securities during the Class Period you may be entitled to compensation without...
- 07/17/2021
|
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages AcelRx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important August 9 Deadline in Securities Class Action – ACRX
- NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) between March 17, 2020 and February 12, 2021, inclusive (the “Class Period”), of the important August 9, 2021 lead plaintiff deadline. SO WHAT: If you purchased AcelRx securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHA
- 07/16/2021
|
AcelRx (ACRX) Inks Agreement With Aguettant for Dzuveo in Europe
- AcelRx (ACRX) enters a licensing agreement for Dzuveo in Europe and an in-licensing agreement for two products in the United States.
- 07/15/2021
|
ACRX Stock Increased 23.77%: Why It Happened
- The stock price of AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) increased by 23.77% today. This is why it happened.
- 07/14/2021
|
5 Reddit Penny Stocks to Watch That Are Moving Right Now
- Are these Reddit penny stocks worth adding to your small-caps watchlist right now? The post 5 Reddit Penny Stocks to Watch That Are Moving Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 07/14/2021
|
ROSEN, A LEADING LAW FIRM, Encourages AcelRx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important August 9 Deadline in Securities Class Action - ACRX
- New York, New York--(Newsfile Corp. - July 14, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) between March 17, 2020 and February 12, 2021, inclusive (the "Class Period"), of the important August 9, 2021 lead plaintiff deadline.SO WHAT: If you purchased AcelRx securities during the Class Period you may be entitled to compensation without payment of any out of pocket...
- 07/14/2021
|
AcelRx, Aguettant Ink Licensing Agreements For Dzuveo And Two Prefilled Syringe Products
- AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) has agreed to provide a license to Laboratoire Aguettant to commercialize Dzuveo in Europe and give AcelRx two prefilled syringe product candidates for the U.S. Under the Dzuveo licensing agreement, Aguettant will have the right to commercialize Dzuveo in Europe.
- 07/14/2021
|
AcelRx Enters into Licensing Agreement for DZUVEO® in Europe and In-licensing Agreement for Two Products in the U.S.
- HAYWARD, Calif., July 14, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced agreements with Laboratoire Aguettant (Aguettant) providing Aguettant with a license to commercialize DZUVEO in Europe, and providing AcelRx with two innovative pre-filled syringe product candidates for the U.S. Under the DZUVEO licensing agreement, Aguettant will have the right to commercialize DZUVEO in Europe.
- 07/14/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AcelRx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ACRX
- New York, New York--(Newsfile Corp. - July 13, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX) and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-04353, is on behalf of a class consisting of all persons and entities other than Defendants that purchased...
- 07/13/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AcelRx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ACRX
- NEW YORK, July 10, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX) and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-04353, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired AcelRx securities between March 17, 2020 and February 12, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 07/10/2021
|
SHAREHOLDER ALERT: Robbins LLP Reminds Investors of a Class Action Against AcelRX Pharmaceuticals, Inc. (ACRX)
- San Diego, California and Hayward, California--(Newsfile Corp. - July 8, 2021) - Shareholder rights law firm Robbins LLP reminds investors that a class action has been filed on behalf of all purchasers of AcelRx Therapeutics, Inc. (NASDAQ:ACRX) securities between March 17, 2020 and February 12, 2021, against the Company for remedies under the Securities Exchange Act of 1934. AcelRx is a pharmaceutical company that develops and commercializes therapies for the treatment of acute...
- 07/08/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AcelRx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ACRX
- New York, New York--(Newsfile Corp. - July 5, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX) and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-04353, is on behalf of a class consisting of all persons and entities other than Defendants that purchased...
- 07/05/2021
|
ROSEN, A TOP RANKED FIRM, Encourages AcelRx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important August 9 Deadline in Securities Class Action - ACRX
- NEW YORK, July 4, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) between March 17, 2020 and February 12, 2021, inclusive (the "Class Period"), of the important August 9, 2021 lead plaintiff deadline. SO WHAT: If you purchased AcelRx securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 07/04/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AcelRx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ACRX
- NEW YORK, July 1, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX) and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-04353, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired AcelRx securities between March 17, 2020 and February 12, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 07/01/2021
|
SHAREHOLDER ALERT: Robbins LLP Reminds Investors That AcelRX Pharmaceuticals, Inc. (ACRX) is Being Sued for Misleading Shareholders
- SAN DIEGO & HAYWARD, Calif.--(BUSINESS WIRE)---- $ACRX #ACELRX--Shareholder rights law firm Robbins LLP reminds investors that a class action has been filed on behalf of all purchasers of AcelRx Therapeutics, Inc. (NASDAQ:ACRX) securities between March 17, 2020 and February 12, 2021, against the Company for remedies under the Securities Exchange Act of 1934. AcelRx is a pharmaceutical company that develops and commercializes therapies for the treatment of acute pain. The Company's lead product candidate is DSUVI
- 07/01/2021
|
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. (ACRX)
- BENSALEM, Pa., July 1, 2021 /PRNewswire/ -- Law Offices of Howard G.
- 07/01/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AcelRx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ACRX
- New York, New York--(Newsfile Corp. - June 26, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX) and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-04353, is on behalf of a class consisting of all persons and entities other than Defendants that...
- 06/26/2021
|
Rosen, A Top Ranked Law Firm, Encourages AcelRx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important August 9 Deadline in Securities Class Action - ACRX
- New York, New York--(Newsfile Corp. - June 25, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) between March 17, 2020 and February 12, 2021, inclusive (the "Class Period"), of the important August 9, 2021 lead plaintiff deadline.SO WHAT: If you purchased AcelRx securities during the Class Period you may be entitled to compensation without payment of any out of...
- 06/25/2021
|
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of AcelRx Pharmaceuticals, Inc. (ACRX) Investors
- LOS ANGELES, June 25, 2021 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX) securities between March 17, 2020 and February 12, 2021 , inclusive (the "Class Period").
- 06/25/2021
|
ACRX Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds AcelRx Pharmaceuticals, Inc. Investors of Class Action and Encourages Investors to Contact the Firm
- New York, New York--(Newsfile Corp. - June 24, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or "the Company") (NASDAQ: ACRX) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired AcelRx securities between March 17, 2020 and February 12, 2021, (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site:...
- 06/24/2021
|
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AcelRx Pharmaceuticals, Inc. Investors With Losses Over $100K to Secure Counsel Before Important August 9 Deadline in Securities Class Action – ACRX
- NEW YORK--(BUSINESS WIRE)-- #ACRX--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) between March 17, 2020 and February 12, 2021, inclusive (the “Class Period”), of the important August 9, 2021 lead plaintiff deadline. SO WHAT: If you purchased AcelRx securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHA
- 06/23/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AcelRx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ACRX
- NEW YORK, June 22, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX) and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-04353, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired AcelRx securities between March 17, 2020 and February 12, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 06/22/2021
|
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. (ACRX)
- LOS ANGELES--(BUSINESS WIRE)---- $ACRX #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming August 9, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired AcelRx Pharmaceuticals, Inc. (“AcelRx” or the “Company”) (NASDAQ: ACRX) securities between March 17, 2020 and February 12, 2021, inclusive (the “Class Period”). If you suffered a loss on your AcelRx investments or would like to inquire about potentially
- 06/18/2021
|
ACRX INVESTOR ALERT: ROSEN, A LEADING AND LONGSTANDING LAW FIRM, Encourages AcelRx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ACRX
- NEW YORK, June 17, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) between March 17, 2020 and February 12, 2021, inclusive (the "Class Period"), of the important August 9, 2021 lead plaintiff deadline. SO WHAT: If you purchased AcelRx securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 06/17/2021
|
ACRX Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies AcelRx Pharmaceuticals, Inc. Investors of Class Action and Encourages Investors to Contact the Firm
- NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or "the Company") (NASDAQ: ACRX) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired AcelRx securities between March 17, 2020 and February 12, 2021, (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/
- 06/17/2021
|
AcelRx Announces Agreement with FDA Addressing the Warning Letter Received for DSUVIA® Promotional Materials
- HAYWARD, Calif., June 17, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced it has reached agreement with the Food and Drug Administration (FDA) with regards to finalizing corrective actions AcelRx has taken or plans to take in response to the previously announced FDA warning letter, dated February 11, 2021, regarding certain DSUVIA promotional materials.
- 06/17/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AcelRx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ACRX
- NEW YORK, June 16, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX) and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-04353, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired AcelRx securities between March 17, 2020 and February 12, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 06/16/2021
|
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. (ACRX)
- BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming August 9, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased AcelRx Pharmaceuticals, Inc. (“AcelRx” or the “Company”) (NASDAQ: ACRX) securities between March 17, 2020 and February 12, 2021, inclusive (the “Class Period”). Investors suffering losses on their AcelRx investments are encouraged to contact the Law Offices of Howard G. Smith to discuss the
- 06/16/2021
|
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of AcelRx Pharmaceuticals, Inc. (ACRX) Investors
- LOS ANGELES--(BUSINESS WIRE)---- $ACRX #investors--The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of AcelRx Pharmaceuticals, Inc. (ACRX) Investors
- 06/15/2021
|
SHAREHOLDER ALERT: Robbins LLP Announces that AcelRX Pharmaceuticals, Inc. (ACRX) is Being Sued for Misleading Shareholders
- SAN DIEGO & HAYWARD, Calif.--(BUSINESS WIRE)---- $ACRX #ACRX--Shareholder rights law firm Robbins LLP announces that a class action has been filed on behalf of all purchasers of AcelRx Therapeutics, Inc. (NASDAQ:ACRX) securities between March 17, 2020 and February 12, 2021, against the Company for remedies under the Securities Exchange Act of 1934. AcelRx is a pharmaceutical company that develops and commercializes therapies for the treatment of acute pain. The Company's lead product candidate is DSUVIA, a 30
- 06/14/2021
|
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of AcelRx Pharmaceuticals, Inc. (ACRX) Investors
- LOS ANGELES--(BUSINESS WIRE)---- $ACRX #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired AcelRx Pharmaceuticals, Inc. (“AcelRx” or the “Company”) (NASDAQ: ACRX) securities between March 17, 2020 and February 12, 2021, inclusive (the “Class Period”). AcelRx investors have until August 9, 2021 to file a lead plaintiff motion. If you suffered a loss on your
- 06/14/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AcelRx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ACRX
- New York, New York--(Newsfile Corp. - June 12, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX) and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-04353, is on behalf of a class consisting of all persons and entities other than Defendants that purchased...
- 06/12/2021
|
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages AcelRx Pharmaceuticals, Inc. Investors With Losses to Secure Counsel Before Important August 9 Deadline in Securities Class Action - ACRX
- NEW YORK, June 11, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) between March 17, 2020 and February 12, 2021, inclusive (the "Class Period"). A class action lawsuit has already been filed.
- 06/11/2021
|
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES--(BUSINESS WIRE)---- $ACRX #ACRX--SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc.
- 06/11/2021
|
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of AcelRx Pharmaceuticals, Inc. (ACRX) Investors
- BENSALEM, Pa.--(BUSINESS WIRE)---- $ACRX #CLASSACTION--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased AcelRx Pharmaceuticals, Inc. (“AcelRx” or the “Company”) (NASDAQ: ACRX) securities between March 17, 2020 and February 12, 2021, inclusive (the “Class Period”). AcelRx investors have until August 9, 2021 to file a lead plaintiff motion. Investors suffering losses on their AcelRx investments are encouraged to contact the Law Offices of Howard G.
- 06/11/2021
|
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of AcelRx Pharmaceuticals, Inc. (ACRX) on Behalf of Investors
- LOS ANGELES--(BUSINESS WIRE)---- $ACRX #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of AcelRx Pharmaceuticals, Inc. (“AcelRx” or the “Company”) (NASDAQ: ACRX) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your AcelRx investments or would like to inquire about potentially pursuing claims to recover your loss under the federal secur
- 06/10/2021
|
ACRX Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies AcelRx Pharmaceuticals, Inc. Investors of Class Action and Encourages Investors to Contact the Firm
- NEW YORK, June 10, 2021 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or "the Company") (NASDAQ: ACRX) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired AcelRx securities between March 17, 2020 and February 12, 2021, (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/acrx.
- 06/10/2021
|
The Law Offices of Frank R. Cruz Announces Investigation of AcelRx Pharmaceuticals, Inc. (ACRX) on Behalf of Investors
- LOS ANGELES--(BUSINESS WIRE)---- $ACRX #investors--The Law Offices of Frank R. Cruz Announces Investigation of AcelRx Pharmaceuticals, Inc. (ACRX) on Behalf of Investors
- 06/09/2021
|
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES--(BUSINESS WIRE)---- $ACRX #ACRX--SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc.
- 06/09/2021
|
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of AcelRx Pharmaceuticals, Inc. (ACRX) on Behalf of Investors
- BENSALEM, Pa.--(BUSINESS WIRE)---- $ACRX #CLASSACTION--Law Offices of Howard G. Smith announces an investigation on behalf of AcelRx Pharmaceuticals, Inc. (“AcelRx” or the “Company”) (NASDAQ: ACRX) investors concerning the Company's possible violations of federal securities laws. AcelRx is a pharmaceutical company that develops therapies for the treatment of acute pain. One of its lead product candidates is DSUVIA, which has been approved by the U.S. Food and Drug Administration (“FDA”) for the management of acute pa
- 06/09/2021
|
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages AcelRx Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline – ACRX
- NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) between March 17, 2020 and February 12, 2021, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 9, 2021. SO WHAT: If you purchased AcelRx securities during the Class
- 06/09/2021
|
ACELRX PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against AcelRx Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
- NEW YORK--(BUSINESS WIRE)-- #AcelRX--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of investors that purchased AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) securities between March 17, 2020 and February 12, 2021, both dates inclusive (the “Class Period”). Investors have until August 9, 2021 to apply to the Court to be appointed a
- 06/08/2021
|
Pomerantz Law Firm Announces the Filing of a Class Action Against AcelRx Pharmaceuticals, Inc. and Certain Officers - ACRX
- NEW YORK, June 8, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX) and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-04353, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired AcelRx securities between March 17, 2020 and February 12, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 06/08/2021
|
Rapid Discharge with Minimal PACU Opioids was Key Message During Presentation of DSUVIA® For Analgesia in Plastic Surgery Procedures at the California Society of Plastic Surgeons Annual Meeting
- HAYWARD, Calif., June 1, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced important findings from a podium presentation on DSUVIA (sufentanil sublingual tablet 30 mcg) during the Best Papers of the Regional Societies session at the California Society of Plastic Surgeons 71st Annual Meeting in Monterey CA.
- 06/01/2021
|
AcelRx Pharmaceuticals: A Bullish View In 3 Song Titles
- AcelRx Pharmaceuticals: A Bullish View In 3 Song Titles
- 05/31/2021
|
Presentation on the Use of DSUVIA® for Plastic Surgery Procedures Selected for "Best Papers" Session at the California Society of Plastic Surgeons Annual Meeting
- HAYWARD, Calif., May 26, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced an upcoming podium presentation on DSUVIA (sufentanil sublingual tablet 30 mcg) which was selected for the Best Papers of the Regional Societies session at the California Society of Plastic Surgeons 71st Annual Meeting in Monterey CA.
- 05/26/2021
|
AcelRx Pharmaceuticals: Moving Closer To An Attractive Risk-Reward
- AcelRx Pharmaceuticals: Moving Closer To An Attractive Risk-Reward
- 05/21/2021
|
Biotech Penny Stocks Are On Fire Today, Here's 3 to Watch Under $5
- Biotech penny stocks continue to heat up; here's 4 under $5 to look into The post Biotech Penny Stocks Are On Fire Today, Here's 3 to Watch Under $5 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 05/18/2021
|
AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vince Angotti on Q1 2021 Results - Earnings Call Transcript
- AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vince Angotti on Q1 2021 Results - Earnings Call Transcript
- 05/17/2021
|
AcelRx Pharmaceuticals: Q1 Earnings Insights
- Shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) decreased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 60.00% year over year to ($0.08), which were in line with the estimate of ($0.08).
- 05/17/2021
|
AcelRx's Dsuvia Shows Reduction In Postoperative Opioids Compared To Control Group
- AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) has announced a poster presentation at the Annual Regional Anesthesiology and Acute Pain Medicine Meeting reviewing the results of a study on the intraoperative administration of Dsuvia (sufentanil sublingual tablet, SST) 30 mcg for the management of acute pain in an ambulatory surgery center. The primary objective of this study was to determine if SST 30 mcg given before emergence from anesthesia was efficacious in reducing initial post-anesthesia care unit pain scores compared to a control group.
- 05/13/2021
|
Study of DSUVIA® Showing Significant Reduction in Postoperative Opioids and Better OBAS Scores Compared to Control Group to be Presented at the American Society of Regional Anesthesia (ASRA) Annual Meeting
- HAYWARD, Calif., May 13, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in a medically supervised setting, today announced a poster presentation at the 46th Annual Regional Anesthesiology and Acute Pain Medicine Meeting reviewing the results of a study on the intraoperative administration of DSUVIA (sufentanil sublingual tablet; SST) 30 mcg for the management of acute pain in an ambulatory surgery center.
- 05/13/2021
|
AcelRx Pharmaceuticals (ACRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
- AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 05/03/2021
|
AcelRx To Test Dsuvia In Patients On Buprenorphine Requiring A Surgical Procedure
- AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) has announced an investigator-initiated study to assess the perioperative use of Dsuvia (sufentanil sublingual tablet) for same-day surgical procedures in patients on buprenorphine therapy for opioid-use disorder or chronic pain management. The study will evaluate the efficacy and safety of Dsuvia for perioperative management of surgical pain in patients on buprenorphine treatment.
- 04/08/2021
|
AcelRx Announces an Investigator-Initiated Study of DSUVIA® in Patients Taking Buprenorphine Who Require a Surgical Procedure
- REDWOOD CITY, Calif., April 8, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced an investigator-initiated study at Montefiore Medical Center evaluating the perioperative use of DSUVIA (sufentanil sublingual tablet 30 mcg) for same-day surgical procedures in patients on buprenorphine therapy for opioid-use disorder or for chronic pain management.
- 04/08/2021
|
AcelRx Pharmaceuticals Announces Appointment of Marina Bozilenko to the Board of Directors
- REDWOOD CITY, Calif., March 31, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the appointment of Marina Bozilenko as an independent member of the company's Board of Directors.
- 03/31/2021
|
AcelRx Pharmaceuticals Announces Clinical Data Reporting High Ratings for Healthcare Professional and Patient Satisfaction Following Use of DSUVIA® for Acute Pain in Hospital Settings
- REDWOOD CITY, Calif., March 25, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the publication of a pooled analysis of Phase 3 data on the use of DSUVIA for acute pain management in the postoperative and emergency department settings in the Journal of Pain Research.
- 03/25/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AcelRx Pharmaceuticals, Inc. (ACRX)
- New York, New York--(Newsfile Corp. - March 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether AcelRx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the...
- 03/21/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AcelRx Pharmaceuticals, Inc. (ACRX)
- NEW YORK, March 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX). Such investors are advised to contact Robert S.
- 03/18/2021
|
AcelRx Pharmaceuticals, Inc. (ACRX) Management on Q4 2020 Results - Earnings Call Transcript
- AcelRx Pharmaceuticals, Inc. (ACRX) Management on Q4 2020 Results - Earnings Call Transcript
- 03/15/2021
|
AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Lags Revenue Estimates
- AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 16.67% and -1.60%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 03/15/2021
|
AcelRx Pharmaceuticals: Q4 Earnings Insights
- Shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 44.44% year over year to ($0.10), which were in line with the estimate of ($0.10).
- 03/15/2021
|
AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
- REDWOOD CITY, Calif., March 15, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its fourth quarter and full year 2020 financial results.
- 03/15/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AcelRx Pharmaceuticals, Inc. (ACRX)
- New York, New York--(Newsfile Corp. - March 14, 2021) - Pomerantz LLP is investigating claims on behalf of investors of AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether AcelRx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the...
- 03/14/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AcelRx Pharmaceuticals, Inc. (ACRX)
- NEW YORK, March 12, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX). Such investors are advised to contact Robert S.
- 03/12/2021
|
AcelRx to Host Fourth Quarter and Full Year 2020 Financial Results Call and Webcast on March 15, 2021
- REDWOOD CITY, Calif., March 8, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release fourth quarter financial results after market close on Monday, March 15, 2021. AcelRx management will host a live...
- 03/08/2021
|
Will AcelRx Pharmaceuticals (ACRX) Report Negative Q4 Earnings? What You Should Know
- AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 03/08/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AcelRx Pharmaceuticals, Inc. (ACRX)
- New York, New York--(Newsfile Corp. - March 7, 2021) - Pomerantz LLP is investigating claims on behalf of investors of AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether AcelRx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the...
- 03/07/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AcelRx Pharmaceuticals, Inc. (ACRX)
- New York, New York--(Newsfile Corp. - February 22, 2021) - Pomerantz LLP is investigating claims on behalf of investors of AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether AcelRx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the...
- 02/22/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AcelRx Pharmaceuticals, Inc. (ACRX)
- NEW YORK, Feb. 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980....
- 02/18/2021
|
AcelRx Pharmaceuticals: Waiting For The Numbers To Close The Gap
- It has been over two years since DSUVIA's approval, but AcelRx is finally starting to record some sales. The launch took longer than expected and the share price was punished. The Department of Defense is expected to receive ~$30M of DSUVIA in the coming years. The DoD contracts should bolster the early commercial numbers until the hospital numbers kick-in.
- 02/14/2021
|
Why AcelRx Pharmaceuticals Stock Is Sinking Today
- The company announced the pricing of a public stock offering.
- 01/20/2021
|
Do Options Traders Know Something About AcelRx (ACRX) Stock We Don't?
- Investors need to pay close attention to AcelRx (ACRX) stock based on the movements in the options market lately.
- 01/13/2021
|
AcelRx Pharmaceuticals to Present at LD Micro Main Event
- REDWOOD CITY, Calif., Dec. 9, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced that management will be...
- 12/09/2020
|
AcelRx Pharmaceuticals Announces Partnership with the National Rural Health Association
- REDWOOD CITY, Calif., Dec. 4, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced a partnership with the...
- 12/04/2020
|
AcelRx Pharmaceuticals: The $1 Million Questions
- Acelrx shares plummeted after the company released third quarter earnings. However, numbers were significantly up compared to any prior period.
- 11/11/2020
|
AcelRx Pharmaceuticals to Present at Credit Suisse 29th Annual Virtual Healthcare Conference
- REDWOOD CITY, Calif., Nov. 6, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced that management will be...
- 11/06/2020
|
AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vincent Angotti on Q3 2020 Results - Earnings Call Transcript
- AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vincent Angotti on Q3 2020 Results - Earnings Call Transcript
- 11/05/2020
|
Wall Street Breakfast: The Week Ahead
- Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.
- 08/30/2020
|
Stocks To Watch: Nvidia, Intel And Zoom Look To Dazzle
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
- 08/29/2020
|
AcelRx Pharmaceuticals Announces Publication of Clinical Data on Reduced Opioid Use and Reduced Time in the Postanesthesia Care Unit (PACU) Following Preoperative Administration of DSUVIA®
- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the publication of a study entitled "Reduced Opioid Use and Reduced Time in the Postanesthesia Care Unit Following Preoperative Administration of Sublingual Sufentanil in an Ambulatory Surgery Setting" by Christian Tvetenstrand, MD and Michael Wolff, MD, in the Journal of Clinical Anesthesia and Pain Management.
- 08/19/2020
|
AcelRx Pharmaceuticals (ACRX) Moves to Buy: Rationale Behind the Upgrade
- AcelRx Pharmaceuticals (ACRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- 08/11/2020
|
AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Lags Revenue Estimates
- AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 42.86% and -25.03%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- 08/10/2020
|
AcelRx Pharmaceuticals Reports Second Quarter 2020 Financial Results
- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its second quarter 2020 financial results.
- 08/10/2020
|
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings
- Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...
- 08/09/2020
|
Tilray (TLRY) to Report Q2 Earnings: What's in the Cards?
- Stocks Analysis by Zacks Investment Research covering: Apple Inc, Ocular Therapeutix Inc, Tilray Inc. Read Zacks Investment Research's latest article on Investing.com
- 08/06/2020
|
AcelRx Pharmaceuticals (NASDAQ:ACRX) Lowered to “Hold” at Zacks Investment Research
- Zacks Investment Research lowered shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) from a buy rating to a hold rating in a research note published on Friday, Zacks.com reports. According to Zacks, “AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: […]
- 08/04/2020
|
AcelRx to Host Second Quarter 2020 Financial Results Call and Webcast on Monday, August 10th, 2020
- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release second quarter financial results after market close on Monday, August 10, 2020. AcelRx management will host a live webcast and conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on August 10, 2020 to discuss the financial results and provide an update on the company's business.
- 08/03/2020
|
AcelRx Pharmaceuticals (NASDAQ:ACRX) Upgraded to Buy by Zacks Investment Research
- Zacks Investment Research upgraded shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) from a sell rating to a buy rating in a research report released on Wednesday, Zacks.com reports. Zacks Investment Research currently has $1.25 target price on the specialty pharmaceutical company’s stock. According to Zacks, “AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development […]
- 08/02/2020
|
Earnings Preview: AcelRx Pharmaceuticals (ACRX) Q2 Earnings Expected to Decline
- AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/27/2020
|
New Forecasts: Here's What Analysts Think The Future Holds For AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX)
- Celebrations may be in order for AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) shareholders, with the analysts delivering...
- 07/25/2020
|
AcelRx Announces Exclusive Distribution and Promotion Partnership for DSUVIA®
- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced an agreement to market DSUVIA®, a sublingual opioid tablet in a single-dose applicator, within the dental and oral surgery markets in the United States exclusively through Zimmer Biomet's Dental division. The agreement expands the U.S. availability of the non-invasive, sublingual analgesic for use by dental healthcare professionals in medically supervised settings who currently use injectable opioids for surgical analgesia.
- 07/23/2020
|
AcelRx Announces $10 Million Common Stock Offering Priced At The Market
- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced it has entered into an agreement with funds affiliated with Armistice Capital and Rock Springs Capital for the sale of 9,433,962 shares of common stock at $1.06 per share, the closing market price on July 22, 2020. AcelRx estimates gross proceeds from the offering of approximately $10.0 million. The closing of the transaction is expected to occur by July 24, 2020, subject to satisfaction of customary closing conditions.
- 07/23/2020
|
Crédito privado: fundos terão que alongar prazos de resgate para entregar melhores retornos, dizem gestores
- Gestores da ARX, DLM Invista e SPX falaram sobre as perspectivas e as mudanças em curso na renda fixa, durante painel da Expert XP
- 07/16/2020
|
AcelRx: Clever Solution To Painful Problem (NASDAQ:ACRX)
- AcelRx has two approved sufentanil-based pain relief therapies. AcelRx's Dsuvia started its launch in the slow lane. AcelRx's disintegrating Tetraphase arrangem
- 06/26/2020
|
La Jolla Pharmaceutical Rekindles Interest In Tetraphase With Sweetened Offer
- The bidding war for Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) seems to be far from over.
What Happened: Tetraphase announced Monday that La Jolla Pharmaceutical Company...
- 06/22/2020
|
Trade Alert: The Independent Chairman Of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), Adrian Adams, Has Just Spent US$129k Buying 133% More Shares
- Investors who take an interest in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) should definitely note that the...
- 06/17/2020
|
ACELRX PHARMACEUTICALS INC : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K) | MarketScreener
|
ARC Resources (TSE:ARX) Downgraded by Scotiabank to Sector Perform
- Scotiabank downgraded shares of ARC Resources (TSE:ARX) from an outperform rating to a sector perform rating in a research note published on Monday, BayStreet.CA reports. Scotiabank currently has C$7.00 target price on the oil and gas exploration company’s stock, down from their prior target price of C$8.00. Several other analysts also recently weighed in on […]
- 06/16/2020
|
AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) CEO Vincent J. Angotti Buys 7,547 Shares of Stock
- AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) CEO Vincent J. Angotti acquired 7,547 shares of the company’s stock in a transaction on Monday, June 15th. The stock was acquired at an average price of $1.33 per share, for a total transaction of $10,037.51. The transaction was disclosed in a filing with the SEC, which can be accessed through […]
- 06/16/2020
|
Hummingbird Resources Is Giving Away 49% Of The Dugbe Gold Project For Peanuts (OTCMKTS:HUMRF)
- ARX to earn 49% in Dugbe by investing $10 million in exploration and delivering a DFS. The previous deal with a ARX foresaw the investment of $30 million in exp
- 06/10/2020
|
The Daily Biotech Pulse: Keytruda Setback For Merck, Denali Pulls The Plug On Neurological Asset
|
Edited Transcript of ACRX earnings conference call or presentation 16-Mar-20 12:30pm GMT
- Q4 2019 AcelRx Pharmaceuticals Inc Earnings Call
- 06/08/2020
|
Merger Arbitrage Mondays - Tiffany Experiences Wild Gyrations
- Merger activity increased last week with one new deal announced. The acquisition of Tetraphase Pharmaceuticals by Melinta Therapeutics for $55 million. Yatra On
- 06/08/2020
|
The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peak (Biotech Stocks Hitting 52-week Highs June 3) * Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) * BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) * Black Diamond Therapeutics Inc (NASDAQ: BDTX) * Fortress Biotech (NASDAQ: FBIO) * Imara Inc (NASDAQ: IMRA) * Inari Medical Inc (NASDAQ: NARI) * Intellia Therapeutics Inc (NASDAQ: NTLA) * Kala Pharmaceuticals Inc (NASDAQ: KALA) * Keros Therapeutics Inc (NASDAQ: KROS) * ORIC Pharmaceuticals Inc (NASDAQ: ORIC) * Phathom Pharmaceuticals Inc (NASDAQ: PHAT) * Pliant Therapeutics Inc (NASDAQ: PLRX) (went public Wednesday) * Protara Therapeutics Inc (NASDAQ: TARA) * Qiagen NV (NYSE: QGEN) * Turning Point Therapeutics Inc (NASDAQ: TPTX) * United Therapeutics Corporation (NASDAQ: UTHR)Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 3) * Cellectar Biosciences Inc (NASDAQ: CLRB) (priced a $20-million common stock offering) * Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX) * Genfit SA (NASDAQ: GNFT)Stocks In Focus Kezar Reports Positive Early Stage Results For KZR-616 In Systemic Lupus Erythematosus Kezar Life Sciences, Inc. (NASDAQ: KZR) announced updated results from the Phase 1b portion of the Phase 1b/2 MISSION study, which is evaluating the safety and tolerability of KZR-616 in patients with systemic lupus erythematosus with and without nephritis, showing overall improvements across seven measures of disease activity.Two of two patients with lupus nephritis experienced a greater than 50% reduction in proteinuria, a biomarker of disease severity, according to the company. A positive safety and tolerability profile was observed with step-up dosing of KZR-616, Kezar said. The stock jumped 48.32% to $6.63 in premarket trading Thursday.AcelRx Ends Bid For Tetraphase Following a bidding war for Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) that saw the contenders sweetening their offers a few times, AcelRx Pharmaceuticals Inc (NASDAQ: ACRX), one of the contenders, said it does not intend to revise further its offer and that the offer is likely to be terminated by Tetraphase.This leaves the path clear for a takeover of Tetraphase by Melinta.AcelRx is eligible to receive a break-up fee of $1.8 million.AcelRx shares were up 1.55% at $1.31 at the time of publication during Thursday's premarket session, while Tetraphase shares were down 1.34% at $2.21. See also: The Week Ahead In Biotech: ASCO, Menlo And Merck FDA Decisions, IPOs In The Spotlight ObSeva Announces Positive Pilot Study Results From Linzagolix In Adenomyosis Obseva SA (NASDAQ: OBSV) announced the publication in the journal Fertility and Sterility of a case report from a pilot study assessing the use of linzagolix for the treatment of uterine adenomyosis. The study showed the patient treated with linzagolix saw alleviation of symptoms such as cessation of bleeding, improvement in pelvic pain, resolution of anemia and shrinkage of uterus at week 12.The symptoms continued to improve with the subsequent 12 weeks of treatment, and the effect lingered at eight weeks following the treatment.Pending confirmation of the results in additional patients, ObsEva said it may pursue additional studies to support supplemental labeling for the treatment of adenomyosis in reproductive-age women.The stock was down 5.66% at $5 premarket. Roche Obtains FDA Emergency Use Authorization For Test To Identify High-Risk Coronavirus Patients Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY) said the FDA has issued an Emergency Use Authorization for the Elecsys IL-6 test, which measures levels of the biomarker interleukin 6 and can be used to help identify patients with confirmed COVID-19 disease who could be at high risk of intubation with mechanical ventilation. AstraZeneca Announces Oncology Partnership With Accent For Up To $1.2B AstraZeneca plc (NYSE: AZN) announced a collaboration with Accent Therapeutics to discover, develop and commercialize transformative therapeutics targeting RNA-modifying proteins for the treatment of cancer.The agreement provides for AstraZeneca paying Accent a $55 million upfront and up to about $1.1 billion in total milestones, plus tiered royalties.In premarket trading, Thursday, AstraZeneca shares were gaining 0.36% to $55.20. Tiziana Gets NIH Grant For Studying Nasal Anti-CD3 Therapy For Alzheimer's Disease TIZIANA LF SCIE/S ADR (NASDAQ: TLSA) said the chairman of its Scientific Advisory Board, Dr. Howard Weiner, has received a competitive research grant from the NIH to investigate nasal anti-CD3 for the treatment of Alzheimer's disease.The company said it has licensed the anti-CD3 mAbs from Brigham and Women's Hospital, Harvard Medical School, Boston, and that it has completed two Phase 1 trials. It also said it expects to initiate two Phase 2 trials shortly for nasally and orally administered Foralumab for the treatment of progressive multiple sclerosis and Crohn's disease, respectively. The stock was adding 4.89% to $6.87 in premarket trading Thursday.EULAR Presentations Gilead Sciences, Inc. (NASDAQ: GILD) and GALAPAGOS NV/S ADR (NASDAQ: GLPG) announced at the at the European League Against Rheumatism, EULAR, E-Congress, Week 52 results from the Phase 3 FINCH 1 and FINCH 3 studies of filgotinib in adults with moderately to severely active rheumatoid arthritis, which demonstrated sustained efficacy and a consistent safety profile with up to 52 weeks of filgotinib treatment across RA patient populations.Novartis AG (NYSE: NVS) announced full 52-week results from the Phase 3 PREVENT trial, which reinforced the substantial and sustained benefits of Cosentyx across the axial spondyloarthritis spectrum."The study found patients treated with Cosentyx 150 mg showed significant and sustained improvements in signs and symptoms of non-radiographic axial spondyloarthritis (nr-axSpA) at 52 weeks," the company said.Novartis shares were rising 0.62% to $86.23 in premarket trading Thursday.Offerings Twist Bioscience Corp (NASDAQ: TWST) said it has priced its underwritten public offering of 3.03 million shares of its common stock at $33 per share for gross proceeds of $100 million. The company expects the offering to close on or about June 8.The stock was down 5.07% at $35.19 premarket. Aileron Therapeutics Inc (NASDAQ: ALRN) said it has commenced an underwritten public offering of shares of its common stock. All the shares earmarked for the offering are sold by the company.The stock was down 13.74% at $1.13 premarket. On The Radar PDUFA Dates The FDA is set to rule on Merck & Co., Inc. (NYSE: MRK) sNDA for its triple combo antibiotic Recarbrio.Related Link: Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates See more from Benzinga * Revisiting The Coronavirus Vaccine Race: Updates On The 10 Candidates In Clinics * The Daily Biotech Pulse: Regulatory Delay For Novartis' Multiple Sclerosis Drug, FSD Gets Nod For COVID-19 Study * The Daily Biotech Pulse: FDA Nod For Roche's Combo Therapy In Liver Cancer, Allena Rips Higher, Pfizer To Invest Up To 0M In Biotechs(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 06/04/2020
|
The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peak
(Biotech Stocks Hitting 52-week Highs June 3)
Arena Pharmaceuticals, Inc. (...
- 06/04/2020
|
Acelrx Pharmaceuticals Will Be Paid a Break-up Fee of ~$1.8M
|
AcelRx Pharmaceuticals Announces It Will Not Further Revise Its Offer to Acquire Tetraphase
|
AcelRx Pharmaceuticals Announces It Will Not Further Revise Its Offer to Acquire Tetraphase
- AcelRx Pharmaceuticals, Inc. (AcelRx) (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it does not intend to revise further its offer under the terms of its previously announced agreement to acquire Tetraphase Pharmaceuticals, Inc. (Tetraphase) (NASDAQ: TTPH), and it expects the agreement to be terminated by Tetraphase. On June 1, 2020, Tetraphase disclosed that its board of directors had determined that an amended proposal from Melinta Therapeutics, Inc. constituted a "Superior Offer" under the terms of the AcelRx Merger Agreement. Under the terms of the agreement, in connection with a termination of the merger agreement, AcelRx will be paid a break-up fee of approximately $1.8 million.
- 06/03/2020
|
20 Healthcare Stocks Moving In Tuesday's Pre-Market Session
|
AcelRx Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
- REDWOOD CITY, Calif., June 1, 2020 /PRNewswire via COMTEX/ --
REDWOOD CITY, Calif., June 1, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX),...
- 06/02/2020
|
AcelRx Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced that management will be providing an overview of the business and company updates at the Jeffries Virtual Healthcare Conference to be held June 2 at 1:30 p.m. ET (10:30 a.m. PT). A live webcast link of the event can be found on the Company's website at http://ir.acelrx.com/upcoming-events. Management will also be hosting one-on-one investor meetings throughout the day.
- 06/02/2020
|
UPDATE: Under Amended Melinta Proposal, Melinta Has Offered To Acquire Tetraphase For $39M In Cash Plus $16M In Cash Potentially Payable Under Contingent Value Rights
|
Merger Arbitrage Mondays - The Bidding War For Tetraphase Pharmaceuticals Comes To An End
- Merger activity ground to a halt last week with no new deals announced. Tetraphase Pharmaceuticals and AcelRx Pharmaceuticals enter into a second amendment. Tex
- 06/01/2020
|
Hedge Funds Have Never Been Less Bullish On AcelRx Pharmaceuticals Inc (ACRX)
- Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]
- 05/29/2020
|
UPDATE: Tetraphase Announces $37M Valuation, $18.7M In Stock Warrants, In Merger With AcelRx
|
AcelRx Pharmaceuticals Announces Revised Merger Agreement With Tetraphase
|
AcelRx Pharmaceuticals Announces Revised Merger Agreement with Tetraphase
- AcelRx Pharmaceuticals, Inc. (AcelRx) (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the execution of an amendment to its merger agreement to acquire Tetraphase Pharmaceuticals, Inc. (Tetraphase) (NASDAQ: TTPH), with revised consideration of $37.0 million in stock and cash based on the AcelRx closing share price on May 28, 2020, plus up to $16.0 million in contingent value rights (CVRs) payable in cash.
- 05/29/2020
|
Tetraphase Announces Second Amendment to Merger Agreement with AcelRx Pharmaceuticals for Increased Consideration
- Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM (eravacycline f
- 05/29/2020
|
The Daily Biotech Pulse: PhaseBio To Start Potential Pivotal COVID-19 Trial, Immunomedics CEO Quits, Tetraphase Receives Sweetened Offer
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 27)
ADC Therapeutics SA (NYSE:...
- 05/28/2020
|
Tetraphase Announces Receipt of Amended Melinta Proposal, Determination of Superior Offer and Notice to AcelRx
|
AcelRx Pharmaceuticals: Finally Light At The End Of The Tunnel (NASDAQ:ACRX)
- Details of the first DOD order for DSUVIA were finally revealed. The initial order of $30M for the Army over three years is small, but it's a sign of things to
- 05/26/2020
|
AcelRx Pharmaceuticals: Lean Back And Watch The Rocket Launch (NASDAQ:ACRX)
- ACRX confirmed final agreement with its cornerstone client, the US Army. Sales from DSUVIA still need to pick up. But reports from doctors using DSUVIA on their
- 05/22/2020
|
Tetraphase Announces Determination of Superior Offer and Notice to AcelRx
- Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline Xerava™ (eravacycline fo
- 05/22/2020
|
Sinus Dilation Devices Market: Poised For a Strong 2021 Outlook Post Covid-19 Scenario
- May 20, 2020 (HTF Market Intelligence via COMTEX) --
AMA Research added a comprehensive research document of 200+ pages on 'Sinus Dilation Devices' market...
- 05/20/2020
|
UPDATE: Tetraphase Board Determine Melinta Offer Could Reasonably Be Expected To Lead To A Superior Offer As Defined In AcelRx Deal
|
Tetraphase Says On May 12 Received Revised Proposal From La Jolla Pharmaceutical For $22.3M In Cash Plus Additional $12.5M In Cash Under Contingent Value; Co.'s Board At This Time Continues To Recommend AcelRx Merger Agreement
|
Edited Transcript of ACRX earnings conference call or presentation 11-May-20 8:30pm GMT
- Q1 2020 AcelRx Pharmaceuticals Inc Earnings Call
- 05/12/2020
|
AcelRx Pharmaceuticals Inc (ACRX) Q1 2020 Earnings Call Transcript
- With me today are Vince Angotti, our Chief Executive Officer; and Dr. Pam Palmer, our Chief Medical Officer. Also, on the call with us today is Dr. Christian Tvetenstrand, who is the Chairman of Surgery and Director of Trauma at Wilson Medical Center, the United Health Services Hospital, who will share his experience with DSUVIA.
- 05/12/2020
|
AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vince Angotti on Q1 2020 Results - Earnings Call Transcript
- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q1 2020 Results Earnings Conference Call May 11, 2020, 04:30 PM ET Company Participants Raffi Asadorian - CFO Vince A
- 05/12/2020
|
AcelRx Pharmaceuticals (ACRX) Reports Q1 Loss, Misses Revenue Estimates
- AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of -33.33% and -85.43%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- 05/11/2020
|
AcelRx Pharmaceuticals Reports First Quarter 2020 Financial Results
- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its first quarter 2020 financial results.
- 05/11/2020
|
Merger Arbitrage Mondays - 3 New Deals, 4 Completions And 1 Failed Deal
- Merger activity increased last week with three new deals announced. The merger of Quintana Energy Services and KLX Energy Services Holdings. Front Yard Resident
- 05/11/2020
|
AcelRx Pharmaceuticals Q1 EPS $(0.200) Misses $(0.170) Estimate, Sales $386.000K Up From $265.000K YoY
|
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
- The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB) gained about 6% for the week.Large-cap pharma names AstraZeneca plc (NYSE: AZN) and Novartis AG (NYSE: NVS) received FDA nods for their heart failure and lung cancer therapies, respectively. After receiving emergency use authorization from the FDA in the U.S., Gilead Sciences, Inc.'s (NASDAQ: GILD) remdesivir obtained full regulatory approval in Japan.Moderna Inc (NASDAQ: MRNA) received the OK to proceed with the Phase 2 trial of its mRNA coronavirus vaccine candidate mRNA-1273.The following are the key events and catalysts that biotech investors need to watch in the coming week. Conferences * Bank of America Securities 2020 HealthCare Virtual Conference: May 12-14 * American Society of Gene and Cell Therapy, or ASGCT, 23rd Virtual Annual Meeting: May 12-15 * 2020 Society for Investigative Dermatology, or SID, Annual Meeting Virtual Conference: May 13-16 * Society for Cardiovascular Angiography and Interventions, or SCAI, 2020 Virtual Conference, Scientific Sessions: May 14-16PDUFA Dates Clovis Oncology Inc (NASDAQ: CLVS) awaits the FDA nod for an expanded indication for its cancer therapy Rubraca. The sNDA seeks approval of Rubraca as a monotherapy treatment for patients with BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer.Clinical Readouts ASGCT Conference Presentations Abeona Therapeutics Inc (NASDAQ: ABEO) is due to present updated interim results from the Transpher A and Transpher B studies, Phase 1/2 trials of ABO-102 and ABO-101, respectively, in mucopolysaccharidosis type IIIA, aka as Sanfilippo syndrome type.Rocket Pharmaceuticals Inc (NASDAQ: RCKT will present updated data from Phase 1/2 FANCOLEN-I study, which is evaluating the safety and efficacy of infusion of autologous CD34 + cells transduced with a lentiviral vector carrying the FANCA gene in patients with Fanconi anemia subtype A, and updates from the Phase 1 LAD-I study that is evaluating its investigational gene therapy RP-L201 to treat severe Leukocyte Adhesion Deficiency-I.Avrobio Inc (NASDAQ: AVRO) is scheduled to make an oral presentation on new data from the Phase 2 trial of AVR-RD-01 for Fabry (Wednesday). The company will also make an oral presentation of new data from the collaborator-sponsored Phase 1/2 clinical trial of AVR-RD-04 in cystinosis. Another oral presentation on new data from a preclinical research program for a gene therapy for Pompe disease is also scheduled for Wednesday.Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) is due to present updated data from the first three cohorts of a Phase 1/2 study of DTX301 in treating ornithine transcarbamylase deficiency (Wednesday). The company will also present updated data from the confirmatory cohort from a Phase 1/2 study of DTX401 in glycogen storage disease Type 1a (Friday).View more earnings on IBBPfizer Inc. (NYSE: PFE) will present Phase 1b data for PF-06939926 in Duchenne muscular dystrophy on Friday.Krystal Biotech Inc (NASDAQ: KRYS) will present a poster on KB407, an HSV-1 based gene therapy vector, for the treatment of cystic fibrosis.See Also: Gilead Works To 'Maximize Global Supply' Of Coronavirus Candidate Remdesivir Amid Threat Of Patent LossOther Readouts Genocea Biosciences Inc (NASDAQ: GNCA) will host a KOL symposium with a live Q&A; for analysts and investors to reflect on the progress of the T cell therapy landscape and provide an in-depth profile of GEN-011 - Genocea's neoantigen cell therapy. (Tuesday)Krystal Biotech is due to present at the SID meeting with results from a Phase 1/2 study of in vivo gene therapy KB105 for treating autosomal recessive congenital ichthyosis as well as results of a Phase 1/2 trial that is evaluating in vivo correction of dystrophic epidermolysis bullosa by direct cutaneous COL7A1 gene replacement.Caladrius Biosciences Inc (NASDAQ: CLBS) will present at the SCAI meeting Thursday with full data from the ESCaPE-CMD study of CLBS16 for the treatment of coronary microvascular dysfunction.Constellation Pharmaceuticals Inc (NASDAQ: CNST) said abstracts of a presentation due at the June 11-14 European Hematology Association meeting will be made available Thursday. The abstract pertains to an interim update from the MANIFEST Phase 2 study that is evaluating CPI-0610 in myelofibrosis.Auris Medical Holding Ltd (NASDAQ: EARS) is due to release top-line data in early May from the Phase 1b trial that is evaluating AM-201 in healthy volunteers. AM-201 is the company's investigational drug for the prevention of antipsychotic-induced weight gain and somnolence.Earnings Monday * Amneal Pharmaceuticals Inc (NYSE: AMRX) (before the market open) * Arbutus Biopharma Corp (NASDAQ: ABUS) (before the market open) * Apyx Medical Corp (NASDAQ: APYX) (before the market open) * Evelo Biosciences Inc (NASDAQ: EVLO) (before the market open) * bluebird bio Inc (NASDAQ: BLUE) (before the market open) * Sesen Bio Inc (NASDAQ: SESN) (before the market open) * Mylan NV (NASDAQ: MYL) (before the market open) * Zimmer Biomet Holdings Inc (NYSE: ZBH) (before the market open) * Wave Life Sciences Ltd (NASDAQ: WVE) (before the market open) * Passage Bio Inc (NASDAQ: PASG) (before the market open) * Pieris Pharmaceuticals Inc (NASDAQ: PIRS) (before the market open) * Oyster Point Pharma Inc (NASDAQ: OYST) (before the market open) * Recro Pharma Inc (NASDAQ: REPH) (before the market open) * Intercept Pharmaceuticals Inc (NASDAQ: ICPT) (before the market open) * Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) (before the market open) * Assertio Therapeutics Inc (NASDAQ: ASRT) (before the market open) * Eagle Pharmaceuticals Inc (NASDAQ: EGRX) (before the market open) * Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) (after the close) * AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) (after the close) * 10X Genomics Inc (NASDAQ: TXG) (after the close) * Aimmune Therapeutics Inc (NASDAQ: AIMT) (after the close) * Acceleron Pharma Inc (NASDAQ: XLRN) (after the close) * Avadel Pharmaceuticals PLC (NASDAQ: AVDL) (after the close) * Pulse Biosciences Inc (NASDAQ: PLSE) (after the close) * Matinas BioPharma Holdings Inc (NYSE: MTNB) (after the close) * CorMedix Inc. (NYSE: CRMD) (after the close) * Castle Biosciences Inc (NASDAQ: CSTL) (after the close) * Omeros Corporation (NASDAQ: OMER) (after the close) * Nabriva Therapeutics PLC - ADR (NASDAQ: NBRV) (after the close) * GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) (after the close) * Halozyme Therapeutics, Inc. (NASDAQ: HALO) (after the close) * Organogenesis Holdings Inc (NASDAQ: ORGO) (after the close) * Neos Therapeutics Inc (NASDAQ: NEOS) (after the close) * Retrophin In (NASDAQ: RTRX) (after the close) * Sangamo Therapeutics Inc (NASDAQ: SGMO) (after the close) * Rockwell Medical Inc (NASDAQ: RMTI) (after the close) * Inovio Pharmaceuticals Inc (NASDAQ: INO) (after the close) * Infinity Pharmaceuticals Inc. (NASDAQ: INFI) (after the close) * Misonix Inc (NASDAQ: MSON) (after the close) * Liquidia Technologies Inc (NASDAQ: LQDA) (after the close) * Cara Therapeutics Inc (NASDAQ: CARA) (after the close) * CymaBay Therapeutics Inc (NASDAQ: CBAY) (after the close) * ChemoCentryx Inc (NASDAQ: CCXI) (after the close) * DURECT Corporation (NASDAQ: DRRX) (after the close) * Endologix, Inc. (NASDAQ: ELGX) (after the close) * Exagen Inc (NASDAQ: XGN) (after the close) * Evolus Inc (NASDAQ: EOLS) (after the close) * Intersect ENT Inc (NASDAQ: XENT) (after the close) * Fate Therapeutics Inc (NASDAQ: FATE) (after the close)Tuesday * BioXcel Therapeutics Inc (NASDAQ: BTAI) (before the market open) * DarioHealth Corp (NASDAQ: DRIO) (before the market open) * Palatin Technologies, Inc. (NYSE: PT) (before the market open) * InspireMD Inc (NYSE: NSPR) (before the market open) * STRATA Skin Sciences Inc (NASDAQ: SSKN) (before the market open) * BioNTech SE - ADR (NASDAQ: BNTX) (before the market open) * aTyr Pharma Inc (NASDAQ: LIFE) (after the close) * Adaptive Biotechnologies Corp (NASDAQ: ADPT) (after the close) * Gossamer Bio Inc (NASDAQ: GOSS) (after the close) * Catabasis Pharmaceuticals Inc (NASDAQ: CATB) (after the close) * Curis, Inc. (NASDAQ: CRIS) (after the close) * Clearpoint Neuro Inc (NASDAQ: CLPT) (after the close) * OncoCyte Corp (NYSE: OCX) (after the close) * Shockwave Medical Inc (NASDAQ: SWAV) (after the close) * Turning Point Therapeutics Inc (NASDAQ: TPTX) (after the close) * Opiant Pharmaceuticals Inc (NASDAQ: OPNT) (after the close) * TapImmune Inc.
- 05/10/2020
|
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
- The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB)...
- 05/10/2020
|
All You Need to Know About AcelRx Pharmaceuticals (ACRX) Rating Upgrade to Buy
- AcelRx Pharmaceuticals (ACRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- 05/08/2020
|
Tetraphase: A Bidding War Shareholders Shouldn't Wait Around For
- Shares in Tetraphase sky-rocketed yesterday after La Jolla announced a non-binding takeover proposal. Tetraphase had already agreed to be bought by AcelRx in Ma
- 05/08/2020
|
Is a Beat in Store for Sunoco (SUN) This Earnings Season?
- Stable earnings from expansive fuel distribution assets are likely to have boosted Sunoco's (SUN) Q1 earnings.
- 05/08/2020
|
All You Need to Know About AcelRx Pharmaceuticals (ACRX) Rating Upgrade to Buy
|
Bidding War Sends Tetraphase Shares Soaring
- Shares of nano-cap Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH), which have never really recovered from a steep sell-off triggered by an adverse clinical readout in late 2015, are surging Thursday after a second bidder emerged.Two-way Race The Watertown, Massachusetts-based company, which has a commercial antibiotic called Xerava to treat serious and life-threatening infections, is being pursued by La Jolla Pharmaceutical Company (NASDAQ: LJPC) after it signed a definitive agreement to be acquired by AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) in mid-March.La Jolla revealed in a filing it submitted a non-binding offer to acquire 100% of the equity of Tetraphase in an all-cash transaction.La Jolla offered for Tetraphase $22 million in cash, plus an additional $12.5 million potentially payable under contingent value rights, or CVRs, to be issued in the transaction.A contingent value right is a derivative instrument, with its value depending on some future event. If the event occurs by the specified date, then a holder of the CVR will get a pre-determined payout, mostly in cash."We are impressed with the growth potential of XERAVA and excited about the potential benefits of combining two companies focused on delivering important therapies to patients in the ICU," said Kevin Tang, Chairman of La Jolla in a letter addressed to the board of Tetraphase.Xerava, which was approved in August 2018, fetched Tetraphase revenues of $3.6 million in 2019 and $1.46 million in the fourth quarter of 2019.La Jolla said it plans to finance the proposed transaction with its cash on hand.Related Link: Attention Biotech Investors: Mark Your Calendar For These May PDUFA DatesAbout three weeks back, Tetraphase announced a definitive merger with AcelRx in a stock-for-stock transaction. The agreement provided for Tetraphase shareholders receiving 0.6303 share of AcelRx stock for each share they hold in Tetraphase, and a CVR, which will give the holders the right to receive aggregate payments of up to $12.5 million on achievement of future Xerava net sales milestones starting in 2021.The stock exchange ratio suggested valuation of $14.4 million at the close of trading March 13, a day before the deal was made public.AcelRx had said then it expects the deal to close in the second quarter. The boards of both companies vetted the transaction and certain stock and warrant holders holding an aggregate of approximately 31% of Tetraphase stock voting in favor of the deal.Merits Of The Offers La Jolla's superior cash offer cash might seem attractive at this juncture, as the world navigates through one of the worst crises it has ever faced."In our view, La Jolla's offer to Tetraphase hinges on an approximate $2.0M up-front premium to AcelRx's offer," H.C. Wainwright analyst Ed Arce said in a note. Despite La Jolla's higher consideration, he said Tetraphase might stick with the AcelRx offer.The terms of CVRs offered by both companies are same, except that La Jolla's CVRs would be paid in cash instead of cash or stock at the acquirer's option."We do not believe La Jolla's unsolicited competing bid is sufficiently compelling to Tetraphase to pull the company away from the current proposed transaction, especially given the amount of commitment and pre-close integration with AcelRx to date," Arce wrote in the note.The TTPH Move Tetraphase was up 89% to $2.63 at time of publication.Latest Ratings for TTPH DateFirmActionFromTo Mar 2020Gabelli & Co.DowngradesHoldSell Jan 2020Gabelli & Co.DowngradesBuyHold Oct 2019Gabelli & Co.UpgradesHoldBuy View More Analyst Ratings for TTPH View the Latest Analyst Ratings See more from Benzinga * The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test * The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 05/07/2020
|
The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks hitting 52-week highs May 6.)
Adverum Biotechnologies Inc...
- 05/07/2020
|
AcelRx Pharmaceuticals (ACRX) Expected to Beat Earnings Estimates: Should You Buy?
- AcelRx Pharmaceuticals (ACRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 05/06/2020
|
Tetraphase (TTPH) to Post Q1 Earnings: What's in the Cards?
- During Tetraphase's (TTPH) upcoming Q1 earnings call, investor focus will be on management's update on the company's pending merger with AcelRx Pharmaceuticals.
- 05/05/2020
|
Tetraphase (TTPH) to Post Q1 Earnings: What's in the Cards?
|
AcelRx to Host First Quarter 2020 Financial Results Call and Webcast on Monday, May 11th, 2020
- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release first quarter financial results after market close on Monday, May 11, 2020. AcelRx management will host a live webcast and conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on May 11, 2020 to discuss the financial results and provide an update on the company's business.
- 05/04/2020
|
One Thing To Remember About The AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Share Price
- If you're interested in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), then you might want to consider its beta (a...
- 05/02/2020
|
OSTK, AR among premarket gainers
- LMP Automotive Holdings (NASDAQ:LMPX) +35%.AgEagle Aerial Systems (NYSEMKT:UAVS) +27%.Soligenix (NASDAQ:SNGX) +25% on positive SGX301 data.Secoo Holding (NASDAQ:SECO) +26% on share repurchase program.
- 04/30/2020
|
AcelRx Announces DSUVIA® Milestone C Approval and Provides Business Update
- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced that DSUVIA achieved Milestone C approval, a decision that clears the path for DSUVIA to be included in military sets, kits and outfits (SKOs).
- 04/30/2020
|
AcelRx shares are trading higher after the company announced DSUVIA has received Milestone C approval.
|
TTPH, FSB, FG, and OPB SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers
- WILMINGTON, Del., April 27, 2020 -- Rigrodsky & Long, P.A. announces that it is investigating: Tetraphase Pharmaceuticals, Inc. (NASDAQ GS: TTPH) regarding possible.
- 04/27/2020
|
Bet on Rising P/E Investing With These Top 5 Stocks
- Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
- 04/24/2020
|
Bet on Rising P/E Investing With These Top 5 Stocks
- Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
- 04/24/2020
|
Bet on Rising P/E Investing With These Top 5 Stocks
|
AcelRx's Shares March Higher, Can It Continue?
|
NTGN, ETFC, TTPH, and MINI SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers
- WILMINGTON, Del., April 21, 2020 -- Rigrodsky & Long, P.A. announces that it is investigating: Neon Therapeutics, Inc. (NASDAQ GS: NTGN) regarding possible breaches of.
- 04/21/2020
|
3 Compelling Penny Stocks With at Least 50% Upside Potential
- Dark clouds are looming over Wall Street, and the storm only appears to be intensifying. The market was dealt another blow on Wednesday April 15, with all three of the major U.S. stock indexes sliding on grim economic data and disappointing earnings reports from banks.According to a Commerce Department
- 04/16/2020
|
ETFC, TTPH, TERP, and MINI SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers
- WILMINGTON, Del., April 14, 2020 -- Rigrodsky & Long, P.A. announces that it is investigating: E*TRADE Financial Corporation (NASDAQ GS: ETFC) regarding possible breaches.
- 04/14/2020
|
TTPH, TERP, MEET, and WLTW SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers
- WILMINGTON, Del., April 02, 2020 -- Rigrodsky & Long, P.A. announces that it is investigating: Tetraphase Pharmaceuticals, Inc. (NASDAQ GS: TTPH) regarding possible.
- 04/02/2020
|
The Zacks Analyst Blog Highlights: AcelRx, BioCryst, Build-A-Bear, CACI and Evercore
- The Zacks Analyst Blog Highlights: AcelRx, BioCryst, Build-A-Bear, CACI and Evercore
- 04/02/2020
|
The Zacks Analyst Blog Highlights: AcelRx, BioCryst, Build-A-Bear, CACI and Evercore
- The Zacks Analyst Blog Highlights: AcelRx, BioCryst, Build-A-Bear, CACI and Evercore
- 04/02/2020
|
The Zacks Analyst Blog Highlights: AcelRx, BioCryst, Build-A-Bear, CACI and Evercore
|
After a Brutal Q1, Q2 Gives a Ray of Hope: 5 Must Buys
- After the Dow sees a quarter as ugly as this year's first quarter, the 124-year old index on average returns 11.8% in the following quarter. There is similar positive trend for the S&P 500 as well.
- 04/01/2020
|
After a Brutal Q1, Q2 Gives a Ray of Hope: 5 Must Buys
- After the Dow sees a quarter as ugly as this year's first quarter, the 124-year old index on average returns 11.8% in the following quarter. There is similar positive trend for the S&P 500 as well.
- 04/01/2020
|
After a Brutal Q1, Q2 Gives a Ray of Hope: 5 Must Buys
|
TTPH, TCO, LM, and WLTW SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers
- WILMINGTON, DE., March 24, 2020 -- Rigrodsky & Long, P.A. announces that it is investigating: Tetraphase Pharmaceuticals, Inc. (NASDAQ GS: TTPH) regarding possible.
- 03/24/2020
|
The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 23.)
Arcutis Biotherapeutics...
- 03/24/2020
|
The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 23.)
Arcutis Biotherapeutics...
- 03/24/2020
|
Moore Kuehn Encourages DLPH, CSFL, TTPH, and FSCT Investors to Contact Law Firm
- Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may ultimately seek increased consideration, additional disclosures, or other
- 03/18/2020
|
AcelRx Acquiring Tetraphase, And Other News: The Good, Bad And Ugly Of Biopharma
- In its latest earnings call, ACRX said it will acquire Tetraphase. AIMT reports more positive data in peanut allergy follow on study. Stemline reports results.
- 03/17/2020
|
The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 16.) * BioNTech SE - ADR (NASDAQ: BNTX) (announced efforts to develop a vaccine for COVID-19) * SUMMIT THERAPEU/S ADR (NASDAQ: SMMT)Down In The Dumps
- 03/17/2020
|
H.C. Wainwright Maintains Buy on AcelRx Pharmaceuticals, Lowers Price Target to $7
|
AcelRx Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q4 sales results.
|
The Week Ahead In Biotech: COVID-19 Updates, Tapering Earnings Flow, Eton's Seizure Drug Review
- The biopharma space bled along with the rest of the market and COVID-19 levered biotechs weren't spared either. Biogen Inc (NASDAQ: BIIB ) was in the news for all wrong reasons, as an employee conference held by the company in Boston from Feb. 24 to 27 was blamed for 77 of the 95 COVID-19 cases reported by Massachusetts as of March 11. The state subsequently had to declare a state of emergency. Several medical meetings scheduled for March and April now stand cancelled. The American Association for Cancer Research said Tuesday the association's 2020 annual meeting scheduled for April 24-29, in San Diego, California is cancelled. Among company-specific developments, Bristol-Myers Squibb Co (NYSE: BMY ) received FDA nod for the Opdivo-Yervoy combo for liver cancer, while AstraZeneca's (NYSE: AZN ) combo drug for ovarian cancer stumbled in a mid-stage trial. Here are some key biotech catalysts that will likely play out in the unfolding week. Conferences 11th Annual Congress on Pulmonology & Respiratory Medicine: March 18-19 in Amsterdam, Netherlands The 2020 annual meetings of the American Academy of Allergy, Asthma and Immunology and the American Academy of Dermatology Association scheduled for the week were cancelled …
- 03/15/2020
|
The Week Ahead In Biotech: COVID-19 Updates, Tapering Earnings Flow, Eton's Seizure Drug Review
- The biopharma space bled along with the rest of the market and COVID-19 levered biotechs weren't spared either.
Biogen Inc (NASDAQ: BIIB) was in the news for all wrong...
- 03/15/2020
|
The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
- Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo Corporation (NASDAQ: MASI ) Down In The Dumps (Biotech stocks that hit 52-week lows March 12.) Abbott Laboratories (NYSE: ABT ) ABIOMED, Inc. (NASDAQ: ABMD ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Achieve Life Sciences Inc (NASDAQ: ACHV ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADDEX THERAPEUT/ADR (NASDAQ: ADXN ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Aileron Therapeutics Inc (NASDAQ: ALRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Akari Therapeutics PLC (NASDAQ: AKTX ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Akero Therapeutics Inc (NASDAQ: AKRO ) Akers Biosciences Inc (NASDAQ: AKER ) Akorn, Inc.
- 03/13/2020
|
The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 12.)
Masimo...
- 03/13/2020
|
Stocks That Hit 52-Week Lows On Thursday
|
AcelRx Announces Confirmed Timing Of Department Of Defense Milestone C Meeting For April
|
AcelRx Announces Agreement For Investigator-Initiated Study Of DSUVIA In Patients Undergoing Spine Surgery
|
The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on Feb. 27)
Global Cord Blood Corp (...
- 02/28/2020
|
The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy
- The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 26.) Co-Diagnostics Inc (NASDAQ: CODX ) Fate Therapeutics Inc (NASDAQ: FATE ) Gilead Sciences, Inc. (NASDAQ: GILD ) Inspire Medical Systems Inc (NYSE: INSP ) (reacted to fourth-quarter results) Mersana Therapeutics Inc (NASDAQ: MRSN ) Moderna Inc (NASDAQ: MRNA ) Nevro Corp (NYSE: NVRO ) (announced fourth-quarter results) Oyster Point Pharma Inc (NASDAQ: OYST ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Revolution Medicines Inc (NASDAQ: RVMD ) Vir Biotechnology Inc (NASDAQ: VIR ) (announced a collaboration with WuXi Biologics for the development of antibodies to treat COVID-19) Down In The Dumps (Biotech stocks that hit 52-week lows Feb. 26.) ABIOMED, Inc. (NASDAQ: ABMD ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Acorda Therapeutics Inc (NASDAQ: ACOR ) AngioDynamics, Inc. (NASDAQ: ANGO ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Auris Medical Holding Ltd (NASDAQ: EARS )(announced publication of results of a study showing anti-epileptic and anti-convulsive activity of betahistine in a mouse model) Blueprint Medicines Corp (NASDAQ: BPMC ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Curis, Inc. (NASDAQ: CRIS ) Enochian Biosciences Inc (NASDAQ: ENOB ) Galectin Therapeutics Inc.
- 02/27/2020
|
Stocks That Hit 52-Week Lows On Thursday
|
The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on Feb. 25)
Arcutis Biotherapeutics...
- 02/26/2020
|
The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 24) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI ) Co-Diagnostics Inc (NASDAQ: CODX )(received CE mark for its coronavirus test) COLLPLANT BIOTE/S ADR (NASDAQ: CLGN ) Gilead Sciences, Inc. (NASDAQ: GILD )(reacted to a statement from WHO that its experimental drug remdesivir could be the one drug that may have efficacy) NGM Biopharmaceuticals Inc (NASDAQ: NGM )( reacted to positive readout for its NASH drug) PAVmed Inc (NASDAQ: PAVM ) TELA Bio Inc (NASDAQ: TELA ) Zynex Inc. (NASDAQ: ZYXI ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on Feb. 24) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Acorda Therapeutics Inc (NASDAQ: ACOR ) ADDEX THERAPEUT/ADR (NASDAQ: ADXN ) AngioDynamics, Inc. (NASDAQ: ANGO ) BioSig Technologies Inc (NASDAQ: BSGM ) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) Endologix, Inc.
- 02/25/2020
|
Stocks That Hit 52-Week Lows On Tuesday
|
AcelRx (ACRX) to Report Q4 Earnings: What's in the Cards?
- During Q4 investors' call, AcelRx (ACRX) is likely to provide an update on the sales uptake of its recently-unveiled product Dsuvia, which is approved for acute pain management.
- 02/24/2020
|
AcelRx (ACRX) to Report Q4 Earnings: What's in the Cards?
|
The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 20.) Akebia Therapeutics Inc (NASDAQ: AKBA ) Aptose Biosciences Inc (NASDAQ: APTO ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) Arcus Biosciences Inc (NYSE: RCUS ) BELLUS Health Inc (NASDAQ: BLU ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Calithera Biosciences Inc (NASDAQ: CALA ) Cue Biopharma Inc (NASDAQ: CUE ) DexCom, Inc. (NASDAQ: DXCM ) Fate Therapeutics Inc (NASDAQ: FATE ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Masimo Corporation (NASDAQ: MASI ) (announced its fourth-quarter results) Medpace Holdings Inc (NASDAQ: MEDP ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Relmada Therapeutics Inc (NASDAQ: RLMD ) Repro-Med Systems, Inc. (NASDAQ: KRMD ) Revance Therapeutics Inc (NASDAQ: RVNC ) (announced $287.5-million debt offering) Revolution Medicines Inc (NASDAQ: RVMD ) (went public Feb. 13) Scpharmaceuticals Inc (NASDAQ: SCPH ) Soligenix, Inc.
- 02/21/2020
|
The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 19) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Anavex Life Sciences Corp (NASDAQ: AVXL ) Arcus Biosciences Inc (NYSE: RCUS ) Ascendis Pharma A/S (NASDAQ: ASND ) AVITA MED LTD/S ADR (NASDAQ: RCEL )(reacted to its half-yearly results) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Calithera Biosciences Inc (NASDAQ: CALA ) ChemoCentryx Inc (NASDAQ: CCXI ) Cue Biopharma Inc (NASDAQ: CUE )(said its therapeutic Immuno-STAT platform will be featured in a Merck & Co., Inc.'s (NYSE: MRK ) presentation at the Antigen Specific Immune Tolerance Drug Development Summit) DexCom, Inc. (NASDAQ: DXCM ) Fate Therapeutics Inc (NASDAQ: FATE ) Fulgent Genetics Inc (NASDAQ: FLGT ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) GENMAB A/S/S ADR (NASDAQ: GMAB )(reacted to its quarterly and full-year results) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Insulet Corporation (NASDAQ: PODD ) Intuitive Surgical, Inc.
- 02/20/2020
|
The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA
- Here's a roundup of top developments in the … Full story available on Benzinga.com
- 02/19/2020
|
Stocks That Hit 52-Week Lows On Tuesday
|
AcelRx Pharmaceuticals (ACRX) Stock Moves -1.14%: What You Should Know
|
AcelRx Sees Prelim. FY19 Sales $2.3M, Cash, Cash Equivalents And Short-Term Investments Of $66.1M As Of Dec. 31
|
Soleno (SLNO) Ends Enrollment in Prader-Willi Syndrome Study
|
Have Faith in Rising P/E: Play 5 Top-Ranked Stocks
|
Top Ranked Momentum Stocks to Buy for January 3rd
|
Jazz Enrolls First Patient in Phase II/III Leukemia Study
|
70 Biggest Movers From Yesterday
|
IFA: The Birth of the New Token ARCS Toward a Society Where the Value and Ideas of Individuals Can Be Converted to Money - The Japan Times
- The new token ARCS will create a platform for visualizing and tokenizing the value held by people. Toward a society where all people can manage and hold sovereignty over their data. TOKYO, December 3, 2019 – IFA CO., LTD. (CEO: Masashi Mizukura) has developed the token ARCS (ticker symbol ARX) based on blockchain technology. The …
- 12/03/2019
|
AcelRx Pharmaceuticals: A More Thorough Review Of Excellent Prospects
|
The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate
|
Stocks That Hit 52-Week Lows On Wednesday
|
Stocks That Hit 52-Week Lows On Tuesday
|
Stocks That Hit 52-Week Lows On Monday
|
Stocks That Hit 52-Week Lows On Thursday
|
AcelRx Pharmaceuticals Q3 EPS $(0.16) Beats $(0.22) Estimate, Sales $608K Miss $960K Estimate
|
The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance
|
Earnings Preview: AcelRx Pharmaceuticals (ACRX) Q3 Earnings Expected to Decline
|
AcelRx Pharmaceuticals (ACRX) Moves to Buy: Rationale Behind the Upgrade
|
AcelRx Pharmaceuticals: Extremely Promising Risk/Reward Profile
|
Week 38 Breakout Forecast: Short-Term Picks To Give You An Edge
|
AcelRx's Dsuvia Launch Just Isn't Enough To Justify Its Growth Premiums
|
Petersen Flynn & Dinsmore Inc Buys Visa Inc, Ishares MSCI India, Constellation Brands Inc, ...
|
AcelRx Pharmaceuticals Q2 EPS $(0.16) Beats $(0.22) Estimate, Sales $941K Miss $1.1M Estimate
|
More Potential FDA Opioid Delays In Nektar's Wake
|
45 Healthcare Stocks Moving In Monday's After-Market Session
|
62 Biggest Movers From Friday
|
Analysts Estimate AcelRx Pharmaceuticals (ACRX) to Report a Decline in Earnings: What to Look Out for
|
35 Stocks Moving In Thursday's Pre-Market Session
|
Credit Suisse Assumes AcelRx Pharmaceuticals at Outperform
|
AcelRx Has A Lot Of Obstacles, But There Could Be A Pot Of Gold At The End
|
AcelRx: The Pain Of The Launch
|
60 Biggest Movers From Friday
|
40 Stocks Moving In Friday's Mid-Day Session
|
Concert Pharma's CTP-692 Positive for Schizophrenia in Phase I
|
64 Biggest Movers From Yesterday
|
AcelRx Pharmaceuticals (ACRX) Upgraded to Buy: Here's Why
|
After Years Of Development, AcelRx's Dsuvia Has Finally Generated Revenue
|
Earnings movers dominate premarket losers
|
AcelRx Pharmaceuticals Q1 EPS $(0.17) Beats $(0.22) Estimate, Sales $265K Miss $750K Estimate
|
